Labopharm Inc. today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act to the U.S. Food and Drug Administration (FDA) for DDS-04A, that provides an effective alternative in the treatment of major depression.
The details can be read here.
No comments:
Post a Comment